CDKL4 (Cyclin-Dependent Kinase-Like 4) is a serine/threonine kinase belonging to the CDK family, which plays roles in cell cycle regulation, transcriptional modulation, and neuronal development. Though less characterized than other CDK members, CDKL4 shares structural homology with CDKL5. a kinase linked to neurodevelopmental disorders like CDKL5 deficiency disorder. CDKL4 is expressed in various tissues, including the brain, and studies suggest potential involvement in cell proliferation, differentiation, and synaptic plasticity. Its exact physiological and pathological functions remain under investigation, with emerging interest in its role in cancers (e.g., glioblastoma, breast cancer) and neurological conditions.
CDKL4 antibodies are essential tools for detecting and studying the protein's expression, localization, and interactions. They enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to explore CDKL4 distribution in tissues or cultured cells. Commercial CDKL4 antibodies are typically developed using immunogenic peptide sequences specific to human CDKL4. validated for specificity via knockout controls or siRNA knockdown. Researchers utilize these antibodies to investigate CDKL4's signaling pathways, post-translational modifications, and potential cross-talk with other kinases. Challenges include ensuring antibody selectivity due to homology within the CDK family. Ongoing research aims to clarify CDKL4's biological significance, with antibodies serving as critical reagents for both basic research and therapeutic target validation.